Global Expansion SK pharmteco’s ongoing facility expansions in Ireland, Sejong (South Korea), and plans to add California peptide production present opportunities to position their CDMO services for multi-region partnerships, cross-border supply chains, and multi-modality programs.

Multi-Modality Capabilities With strengths in small molecules, peptides, and viral vectors (LVV, AAV, AdV), SK pharmteco can address diverse therapeutic pipelines, enabling you to engage clients pursuing combination modalities or rapid tech transfers from clinical to commercial stages.

Strategic Partnerships Recent Lilly contract and a large-scale Sejong investment indicate a track record of securing major pharma collaborations, signaling readiness to scale with new biopharma partners and offering co-development and manufacturing commitments.

High-Value Investments Significant capital expenditure in peptide and viral vector facilities suggests a focus on HPAPIs and complex biologics, providing a sales angle for clients seeking robust GMP capabilities, advanced process development, and reliable supply chains.

Sustainability & Tech Enablement Active participation in sustainability initiatives and a tech stack including Power BI and SAP points to data-driven operations and ESG-aligned partnerships, which can be attractive to customers prioritizing transparent reporting and efficient program management.